| Outcome Measures: |
Primary: Change in fasting blood glucose, Using glucose oxidase method for assessment of blood glucose and subtracting pre-treatment from post-treatment values, baseline and 3 months later|Change in plasma insulin level, Subtracting pre-treatment from post-treatment values of plasma insulin, baseline and 3 months later|Change in HOMA-IR index, HOMA-IR will be calculated for all patients at baseline and 3 months later., baseline and 3 months later|Change in HOMA-B index, HOMA-B will be calculated for all patients at baseline and 3 months later., baseline and 3 months later.|Change in HbA1c, Subtracting pre-treatment from post-treatment values of HbA1C, baseline and 3 months later | Secondary: Changes in TNF-alfa serum level, Subtracting pre-treatment from post-treatment values of TNF-alfa., baseline and 3 months later|Changes in malondialdehyde serum level (MDA), Subtracting pre-treatment from post-treatment values of MDA., baseline and 3 months later|Changes in neurotensin serum levels, Subtracting pre-treatment from post-treatment values of neurotensin serum levels., baseline and 3 months later|Ewing score, Subtracting pre-treatment from post-treatment changes in summation of the cardiac autonomic reflex tests (CARTs) including heart response to a deep breathing test, changes in immediate heart rate response to standing, and changes in blood pressure response to sustained handgrip testing., baseline and 3 months later|Changes of Michigan Neuropathy Screening Instrument, A 15-item questionnaire (MNSIQ) is used to assess deformation, infection, skin thickening of the skin's stratum corneum, and ulcers. MNSIQ was designed to screen for diabetic neuropathy through questionnaires on 15 questions that are related to neuropathic symptoms (pain, temperature, and sensation). Two of 15 (number 4 and 10) are vascular symptoms and are excluded from the total score regardless of the results. If you answered 'No' to questions 7 and 13, you will get 1 point. In the end, scores ranging from 0 to 13 indicate that the higher the score, the more severe the neuropathic symptoms., baseline and 3 months later|Changes of Michigan Neuropathy Screening Instrument(MNSIE), A foot test (MNSIE) is used to assess deformation, infection, skin thickening of the skin's stratum corneum, and ulcers. MNSIE evaluates foot shape, foot ulceration, ankle reflex, sense of vibration of big toe, monofilament right and left. The score ranges from point 0 to 10, and when the score is above 2, it is diagnosed as neuropathy., baseline and 3 months later|Changes of Douleur Neuropathique-4 (DN4) questionnaire (DN4), DN4 Neuropathic Pain Diagnostic Questionnaire which reflect positive symptoms for pain ( burning, painful cold, electric shocks, ), baseline and 3 months later | Other: Assessment of changes in patients' quality of life, Using Diabetes Quality Of Life questionnaire (DQOL), baseline and 3 months later|Major adverse cardiovascular events (MACE), Major adverse cardiovascular events (MACE) as non-fatal myocardial infarction (MI), non-fatal stroke, and cardiovascular death., 3 months
|
